Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
John L. Lyles, Aditi Mulgund, Laura Bauman, et al.
Inflammatory Bowel Diseases (2020) Vol. 27, Iss. 4, pp. 482-492
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Adam S. Cheifetz, María T. Abreu, Waqqas Afif, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 10, pp. 2014-2025
Open Access | Times Cited: 151
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Namita Singh, Marla C. Dubinsky
Springer eBooks (2023), pp. 445-456
Closed Access | Times Cited: 16
Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease
Patrick Rowland, Megan McNicol, Ashley Kiel, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 78, Iss. 4, pp. 853-861
Closed Access | Times Cited: 5
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Calling in Your Markers: Can Biomarkers Predict the Response to Anti-TNF Therapy in Pediatric Patients with Crohn’s Disease?
Kevin Watson
Digestive Diseases and Sciences (2025)
Closed Access
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA
Phillip Minar, Ruben J. Colman, Nanhua Zhang, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e077193-e077193
Open Access | Times Cited: 4
Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease
Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 5, pp. 593-603
Open Access | Times Cited: 29
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease
Abigail Samuels, Kaitlin G. Whaley, Phillip Minar
Current Gastroenterology Reports (2023) Vol. 25, Iss. 11, pp. 323-332
Open Access | Times Cited: 7
Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease
Dwight A. Winter, Pauline De Bruyne, J van der Woude, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 1, pp. 62-75
Open Access | Times Cited: 2
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
Eric Cheah, James Guoxian Huang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 10, pp. 1539-1550
Open Access | Times Cited: 6
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White Children
Julia Smith, Chunyan Liu, Andrew F. Beck, et al.
The Journal of Pediatrics (2023) Vol. 260, pp. 113522-113522
Open Access | Times Cited: 6
Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
Akshay Kapoor, Eileen Crowley
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 15
Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients
Stacy A. Kahn, Athos Bousvaros
Journal of Pediatric Gastroenterology and Nutrition (2022) Vol. 75, Iss. 4, pp. 418-422
Closed Access | Times Cited: 9
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics
Ruben J. Colman, S Vuijk, Ron A. A. Mathôt, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 10, pp. 1678-1685
Closed Access | Times Cited: 1
Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn’s Disease
Sabina Ali, Brad Pasternak, Jonathan Moses, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 10, pp. 2075-2083.e1
Closed Access | Times Cited: 1
Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease
Tal Marshanski, Eliana Fanous, Noa Tal, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 564-572
Closed Access | Times Cited: 1
Therapeutic drug monitoring in inflammatory bowel disease: recent developments
Xavier Roblin, Robert D. Little, Nicolas Mathieu, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 10, pp. 575-586
Closed Access | Times Cited: 1
Biological therapy in pediatric age
Francesca Penagini, Lucia Cococcioni, Elena Pozzi, et al.
Pharmacological Research (2020) Vol. 161, pp. 105120-105120
Closed Access | Times Cited: 12
Early Infliximab Clearance Predicts Remission in Children with Crohn’s Disease
Aaron Chung, Matthew Carroll, Patrícia de Almeida, et al.
Digestive Diseases and Sciences (2022) Vol. 68, Iss. 5, pp. 1995-2005
Closed Access | Times Cited: 6
Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine
Ruben J. Colman, Jasbir Dhaliwal, Michael J. Rosen
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 8
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top